Abstract
Background
Though the pathology of optic pathway tumor is mostly pilocytic astrocytoma, the benign tumor behaves like malignant tumor because total resection is not feasible. Adjuvant chemotherapy might be a reasonable strategy for management of these low grade tumors which keep growing. We evaluate the responsiveness of optic pathway tumor to cisplatin-based chemotherapy.
Methods
Patients with unresectable and progressive optic pathway tumors received conventional chemotherapy including cisplatin, etoposide, and vinblastine were enrolled in this study from 1992 to 2007. Patients treated with radiotherapy previously were excluded. Brain MRI was performed every 3 months to evaluate the objective response to chemotherapy.
Results
There are seven girls and nine boys enrolled in this study. The median age at diagnosis was 30 months old (range from 3 months to 11 years old). The median follow-up duration was 81.5 months (range from 24 months to 14.5 years). The pathology showed pilocytic astrocytomas in 11 patients, astrocytoma in one patient, and anaplastic astrocytomas in two patients. The 6-month progression-free survival (PFS) is 100%, 12-month PFS is 81.3%, 3-year PFS is 71.4% and 5-year PFS is 55.5% respectively. The toxicity of the cisplatin-based chemotherapy showed mild bone marrow suppression in 13 patients (81.3%), infection in nine patients (56.3%), gastrointestinal discomfort in seven patients (43.8%), renal insufficiency in two patient (12.5%), cerebral salt wasting syndrome with hyponatremia in one patient (6.25%) and high pitch hearing loss in two patients (12.5%).
Conclusion
Cisplatin-based chemotherapy is an effective regimen for control of progressive optic pathway tumors.
Similar content being viewed by others
References
Alvord EC Jr, Lofton S (1988) Gliomas of the optic nerve or chiasm. Outcome by patients’ age, tumor site, and treatment. J Neurosurg 68:85–98
Beyer RA, Paden P, Sobel DF, Flynn FG (1986) Moyamoya pattern of vascular occlusion after radiotherapy for glioma of the optic chiasm. Neurology 36:1173–1178
Cohen BH, Rothner AD (1989) Incidence, types, and management of cancer in patients with neurofibromatosis. Oncology (Williston Park) 3:23–30
Cohen ME, Duffner PK (1991) Optic pathway tumors. Neurol Clin 9:467–477
Deliganis AV, Geyer JR, Berger MS (1996) Prognostic significance of type 1 neurofibromatosis (von Recklinghausen Disease) in childhood optic glioma. Neurosurgery 38:1114–1118
Dosoretz DE, Blitzer PH, Wang CC, Linggood RM (1980) Management of glioma of the optic nerve and/or chiasm: an analysis of 20 cases. Cancer 45:1467–1471
Dutton JJ (1994) Gliomas of the anterior visual pathway. Surv Ophthalmol 38:427–452
Dutton JJ (1991) Optic nerve gliomas and meningiomas. Neurol Clin 9:163–177
Fisher BJ, Leighton CC, Vujovic O, Macdonald DR, Stitt L (2001) Results of a policy of surveillance alone after surgical management of pediatric low grade gliomas. Int J Radiat Oncol Biol Phys 51:704–710
Grill J, Couanet D, Cappelli C, Habrand JL, Rodriguez D, Sainte-Rose C, Kalifa C (1999) Radiation-induced cerebral vasculopathy in children with neurofibromatosis and optic pathway glioma. Ann Neurol 45:393–396
Hoffman HJ, Humphreys RP, Drake JM, Rutka JT, Becker LE, Jenkin D, Greenberg M (1993) Optic pathway/hypothalamic gliomas: a dilemma in management. Pediatr Neurosurg 19:186–195
Horwich A, Bloom HJ (1985) Optic gliomas: radiation therapy and prognosis. Int J Radiat Oncol Biol Phys 11:1067–1079
Housepian EM, Chi TL (1993) Neurofibromatosis and optic pathways gliomas. J Neurooncol 15:51–55
Hoyt WF, Baghdassarian SA (1969) Optic glioma of childhood. Natural history and rationale for conservative management. Br J Ophthalmol 53:793–798
Imes RK, Hoyt WF (1986) Childhood chiasmal gliomas: update on the fate of patients in the 1969 San Francisco Study. Br J Ophthalmol 70:179–182
Janss AJ, Grundy R, Cnaan A, Savino PJ, Packer RJ, Zackai EH, Goldwein JW, Sutton LN, Radcliffe J, Molloy PT (1995) Optic pathway and hypothalamic/chiasmatic gliomas in children younger than age 5 years with a 6-year follow-up. Cancer 75:1051–1059
Jenkin D, Angyalfi S, Becker L, Berry M, Buncic R, Chan H, Doherty M, Drake J, Greenberg M, Hendrick B (1993) Optic glioma in children: surveillance, resection, or irradiation? Int J Radiat Oncol Biol Phys 25:215–225
Kestle JR, Hoffman HJ, Mock AR (1993) Moyamoya phenomenon after radiation for optic glioma. J Neurosurg 79:32–35
Korones DN, Padowski J, Factor BA, Constine LS (2003) Do children with optic pathway tumors have an increased frequency of other central nervous system tumors? Neuro Oncol 5:116–120
Kuo DJ, Weiner HL, Wisoff J, Miller DC, Knopp EA, Finlay JL (2003) Temozolomide is active in childhood, progressive, unresectable, low-grade gliomas. J Pediatr Hematol Oncol 25:372–378
Kwon Y, Bae JS, Kim JM, Lee DH, Kim SY, Ahn JS, Kim JH, Kim CJ, Kwun BD, Lee JK (2005) Visual changes after gamma knife surgery for optic nerve tumors. Report of three cases. J Neurosurg 102(Suppl):143–146
Laithier V, Grill J, Le Deley MC, Ruchoux MM, Couanet D, Doz F, Pichon F, Rubie H, Frappaz D, Vannier JP, Babin-Boilletot A, Sariban E, Chastagner P, Zerah M, Raquin MA, Hartmann O, Kalifa C (2003) Progression-free survival in children with optic pathway tumors: dependence on age and the quality of the response to chemotherapy–results of the first French prospective study for the French Society of Pediatric Oncology. J Clin Oncol 21:4572–4578
Listernick R, Louis DN, Packer RJ, Gutmann DH (1997) Optic pathway gliomas in children with neurofibromatosis 1: consensus statement from the NF1 Optic Pathway Glioma Task Force. Ann Neurol 41:143–149
Mahoney DH Jr., Cohen ME, Friedman HS, Kepner JL, Gemer L, Langston JW, James HE, Duffner PK, Kun LE (2000) Carboplatin is effective therapy for young children with progressive optic pathway tumors: a Pediatric Oncology Group phase II study. Neuro Oncol 2:213–220
Massimino M, Spreafico F, Cefalo G, Riccardi R, Tesoro-Tess JD, Gandola L, Riva D, Ruggiero A, Valentini L, Mazza E, Genitori L, Di RC, Navarria P, Casanova M, Ferrari A, Luksch R, Terenziani M, Balestrini MR, Colosimo C, Fossati-Bellani F (2002) High response rate to cisplatin/etoposide regimen in childhood low-grade glioma. J Clin Oncol 20:4209–4216
Oxenhandler DC, Sayers MP (1978) The dilemma of childhood optic gliomas. J Neurosurg 48:34–41
Packer RJ, Lange B, Ater J, Nicholson HS, Allen J, Walker R, Prados M, Jakacki R, Reaman G, Needles MN (1993) Carboplatin and vincristine for recurrent and newly diagnosed low-grade gliomas of childhood. J Clin Oncol 11:850–856
Sayli T, Cemeroglu AP, Tuncer AM, Gurgey A (1993) Acute lymphoblastic leukemia following optic glioma treated by radiotherapy and surgery. Acta Paediatr 82:327–328
Shuper A, Horev G, Kornreich L, Michowiz S, Weitz R, Zaizov R, Cohen IJ (1997) Visual pathway glioma: an erratic tumour with therapeutic dilemmas. Arch Dis Child 76:259–263
Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van GM, van Oosterom AT, Christian MC, Gwyther SG (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for research and treatment of cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205–216
Tow SL, Chandela S, Miller NR, Avellino AM (2003) Long-term outcome in children with gliomas of the anterior visual pathway. Pediatr Neurol 28:262–270
Tym R (1961) Piloid gliomas of the anterior optic pathways. Br J Surg 49:322–331
Wisoff JH, Abbott R, Epstein F (1990) Surgical management of exophytic chiasmatic-hypothalamic tumors of childhood. J Neurosurg 73:661–667
Wong TT, Ho DM, Chang KP, Yen SH, Guo WY, Chang FC, Liang ML, Pan HC, Chung WY (2005) Primary pediatric brain tumors: statistics of Taipei VGH, Taiwan (1975–2004). Cancer 104:2156–2167
Author information
Authors and Affiliations
Corresponding author
Additional information
Ting-Rong Hsu and Kai-Ping Chang contributed equally to this paper.
Rights and permissions
About this article
Cite this article
Hsu, TR., Wong, TT., Chang, FC. et al. Responsiveness of progressive optic pathway tumors to cisplatin-based chemotherapy in children. Childs Nerv Syst 24, 1457–1461 (2008). https://doi.org/10.1007/s00381-008-0707-4
Received:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00381-008-0707-4